lundi 6 juin 2016

Onco Actu du 6 juin 2016 - spécial ASCO


5.5.1 ASCO (général)

CancerLinQ LLC and CI4CC Launch Collaboration to Transform Cancer Data [ASCO]

ASCO’s CancerLinQ™ Extends its Reach – 58 Oncology Practices, 750,000 Patient Records, 1,000 Providers Under Contract, New Partnership Launch With the Nation’s Leading Cancer Informatics Association [ASCO]

5.5.10 ASCO (hémato)

Novel Daratumumab-Based Regimen Slows Multiple Myeloma Progression [ASCO]

VYXEOS scores a 10 over 7+3 [The OBR Blog]

CASTOR Shines in Relapsed/Refractory Multiple Myeloma [The OBR Blog]

Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability [Juno]

Juno Therapeutics’ Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL [Juno]

Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID® Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma [Celgene]

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna® [Novartis]

J&J myeloma drug, in combo regimen, delays worsening of the disease [Reuters]

5.5.11 ASCO (SNC]

Elderly Patients With Glioblastoma Live Longer With Chemoradiation Using Temozolomide [ASCO]

Giving chemotherapy after radiotherapy improves survival for patients with rare brain tumour [Cancer Research UK]

Chemotherapy Improves Outcomes for Certain Patients with Rare Brain Cancer [ASCO]

5.5.12 ASCO (médico-éco)

Precision/Personalized Medicine: Can We Afford Our Success? [Dr. Len]

Why Don’t We Pay As Much Attention To Prevention And Better Cancer Care As We Do To The Next Great New Cancer Drug? [Dr. Len]

Combination Cancer Drug Therapies Raise Cost Concerns [Wall Street Journal]

5.5.14 ASCO (vessie)

Patients With Advanced Bladder Cancer Benefit From Anti-PD-L1 Immunotherapy [ASCO]

Genentech’s Cancer Immunotherapy Tecentriq™ (atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer [Genentech]

Promising Response Rates with Opdivo® (nivolumab) Observed in Advanced Form of Bladder Cancer from Phase 1/2 Study CheckMate -032 [BMS]

Roche therapy helps 24 percent of untreated bladder cancer patients: study [Reuters]

5.5.15 ASCO (biopsies liquides)

Guardant Health Maps Cautious Plans For Blood-Based Cancer Screening [Xconomy]

Large Guardant Health study backs use of 'liquid biopsies' [Reuters]

Liquid Biopsy May Help Guide Treatment Decisions for Advanced Solid Tumors [ASCO]

‘Liquid’ Cancer Test Offers Hope for Alternative to Painful Biopsies [NY Times]

5.5.16 ASCO (médecine de précision)

Innovative Direct-to-Patient Outreach May Accelerate Breast Cancer Research [ASCO]

Defining cancers based on genetic ‘fingerprint’ could help personalise treatment [Cancer Research UK]

Precision Medicine Approach May Expand Therapeutic Options for Patients [ASCO]

'Most exciting cancer treatment since chemotherapy' could save patients using DNA tests [The Telegraph]

5.5.17 ASCO (pancréas)

Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20 [Halozyme]

Data Presented at ASCO 2016 Builds upon Foundation of Abraxane® Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer [Celgene]

Cancer Research UK trial shows improved 5 year survival for pancreatic cancer patients [Cancer Research UK]

Drug combination may extend pancreas cancer survival, trial finds [The Guardian]

Chemotherapy Combination With Capecitabine Extends Survival After Pancreatic Cancer Surgery [ASCO]

5.5.2 ASCO (sein)

Breast cancer: Taking hormonal drugs for up to 15 years can reduce risk - study (BBC News]

Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy [Lilly]

Major weight-loss cancer trial starting [BBC News]

Trial to investigate link between weight, fitness and cancer recurrence [ The Guardian]

Ten Years of Hormone Therapy Reduces Breast Cancer Recurrence Without Compromising Quality of Life [ASCO]

Breast cancer study shows benefit to extended treatment with aromatase inhibitors [STAT]

Study Finds Mylan’s ‘Biosimilar’ Drug Comparable to Roche Cancer Medicine [Wall Street Journal]

Copycat biotech cancer drug works as well as Roche original: study [Reuters]

Biosimilar Shows Comparable Efficacy, Safety to Trastuzumab in Advanced Breast Cancer [ASCO]

Breast cancer drugs should be given for 10 years, study shows [The Guardian]

Extending Estrogen Suppressor May Aid Breast Cancer Patients, Study Says [NY Times]

Mediterranean diet may help stop breast cancer coming back, study says [The Guardian]

5.5.4 ASCO (immunothérapies)

Genetic chaos in tumours could predict responses to immunotherapy (Cancer Research UK]

New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers [Merck]

Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor [Pfizer]

Doubling-up on cancer immunotherapy shows promise, but side effects still a challenge [Cancer Research UK]

Cancer treatment untested in many patients with immune problems [Reuters]

Cancer cell therapies could be approved next year: Juno, Kite Pharma [Reuters]

5.5.5 ASCO (gastro-intestinal)

First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (ipilimumab) Demonstrates Encouraging Clinical Activity in MSI-High Metastatic Colorectal Cancer [BMS]

New pre-surgery technique may make colostomy bags redundant for emergency bowel cancer patients [Cancer Research UK]

Bowel cancer: Stents 'may prevent need for colostomy bags' [BBC News]

5.5.6 ASCO (peau-mélanome)

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting [Merck]

5.5.7 ASCO (gynéco)

Adding Intraperitoneal Chemotherapy Slows Ovarian Cancer Progression [ASCO]

5.5.8 ASCO (poumon)

AbbVie's New Lung Cancer Drug May Extend Patients' Lives, But Could Disappoint Investors [Forbes]

New Antibody Drug Conjugate Shows Early Promise in Small Cell Lung Cancer [ASCO]

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer [Lilly]

ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations [ARIAD]

ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients [ARIAD]

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting [Merck]

New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent [Merck]

Opdivo® (nivolumab) and Yervoy® (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase 1b Study CheckMate -012 [BMS]

Twice a day radiotherapy halves treatment time and is equally good at treating small cell lung cancer [Cancer Research UK]

5.5.9 ASCO (autres organes)

Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma Patients Based on New Data Presented at the 2016 ASCO Annual Meeting [BMS]

Double Stem-Cell Transplant Improves Outcomes for Children with High-Risk Neuroblastoma [ASCO]

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO [Ipsen]